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Epidermal Inactivation of the Glucocorticoid
Receptor Triggers Skin Barrier Defects and
Cutaneous Inflammation
Lisa M. Sevilla1,2, Vı´ctor Latorre1,2, Ana Sanchis1 and Paloma Pe´rez1
The glucocorticoid (GC) receptor (GR) mediates the effects of physiological and pharmacological GC ligands
and has a major role in cutaneous pathophysiology. To dissect the epithelial versus mesenchymal contribution
of GR in developing and adult skin, we generated mice with keratinocyte-restricted GR inactivation (GR
epidermal knockout or GREKO mice). Developing and early postnatal GREKO mice exhibited impaired epidermal
barrier formation, abnormal keratinocyte differentiation, hyperproliferation, and stratum corneum (SC) fragility.
At birth, GREKO epidermis showed altered levels of epidermal differentiation complex genes, proteases and
protease inhibitors which participate in SC maintenance, and innate immunity genes. Many upregulated genes,
including S100a8/a9 and Tslp, also have increased expression in inflammatory skin diseases. Infiltration of
macrophages and degranulating mast cells were observed in newborn GREKO skin, hallmarks of atopic
dermatitis. In addition to increased extracellular signal–regulated kinase activation, GREKO newborn and adult
epidermis had increased levels of phosphorylated signal transducer and activator of transcription 3, a feature of
psoriasis. Although adult GREKO epidermis had a mild phenotype of increased proliferation, perturbation of skin
homeostasis with detergent or phorbol ester triggered an exaggerated proliferative and hyperkeratotic
response relative to wild type. Together, our results show that epidermal loss of GR provokes skin barrier
defects and cutaneous inflammation.
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INTRODUCTION
The glucocorticoid (GC) receptor (GR or Nr3c1) is a ligand-
activated transcription factor that belongs to the nuclear
hormone receptor superfamily and regulates gene expression
through DNA-binding–dependent and –independent mechan-
isms (Revollo and Cidlowski, 2009; Nicolaides et al., 2010). GR
is ubiquitously expressed and mediates the biological and
therapeutical effects of endogenous and synthetic GCs (Revollo
and Cidlowski, 2009; Nicolaides et al., 2010). The wide use of
GC analogs in clinical practice relies on their great efficacy as
anti-inflammatory agents, mostly due to the antagonism bet-
ween ligand-activated GR and the pro-inflammatory NF-kB,
AP-1, and signal transducer and activator of transcription (STAT)
signaling pathways in many cell types (Clark, 2007; Liberman
et al., 2007; De Bosscher and Haegeman, 2009). GCs are
currently used to treat inflammatory skin pathologies, such as
atopic dermatitis (AD) and psoriasis, because of their anti-
proliferative and anti-inflammatory actions in both immune
cells and keratinocytes (Scha¨cke et al., 2002; Elias, 2010). The
mechanisms mediating GR therapeutical actions in skin disease
have been widely studied, however, much less is known about
the role of GR in skin physiology (Pe´rez, 2011).
In rodents, classical studies have shown that exogenous
GCs promote epidermal barrier formation during develop-
ment. Conversely, GC treatment of adult animals perturbs
permeability barrier homeostasis, suggestive of unique roles
for the GR in development and adulthood (Sheu et al., 1991;
Aszterbaum et al., 1993; Hanley et al., 1998; Kao et al.,
2003). We previously demonstrated that ubiquitous ablation
of GR (GR/) leads to major defects in mouse skin
development with impaired keratinocyte differentiation, and
augmented proliferation and apoptosis (Bayo et al., 2008).
Transcriptional profiling of GR/ embryonic skin together
with studies using cultured primary keratinocytes showed
aberrant expression of genes encoding epidermal barrier
proteins (Sevilla et al., 2010). However, these analyses did
not allow for discrimination of the keratinocyte-specific
contribution of GR in skin development and pathophysiol-
ogy. Moreover, GR/ mice had alterations in the synthesis
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and secretion of steroids, which resulted in increased
levels of ACTH and circulating corticosterone that may
contribute to the skin phenotype (Tronche et al., 1999; Bayo
et al., 2008). Above all, perinatal death of GR/ mice
precluded analyzing skin phenotype progression and whether
developmental defects result in increased susceptibility
to skin inflammation in the adult age, as described for
other mouse models featuring epidermal barrier defects
(Segre, 2006; Cork et al., 2009; Elias, 2010; Roberson and
Bowcock, 2010).
To resolve these issues, we generated a mouse model with
constitutive GR inactivation restricted to keratinocytes (GR
epidermal knockout or GREKO mice). In this report, we
describe that GREKO mice exhibited defects in epidermal
development and competence with stratum corneum (SC)
fragility and degranulated mast cells in the dermis. At birth,
GREKO mice showed upregulation of known markers of
cutaneous inflammatory diseases associated with epidermal
barrier defects. The changes in gene expression were
concomitant with increased extracellular signal–regulated
kinase (ERK) and STAT3 activation in GREKO newborn
epidermis. Although the skin in adult mice had a milder
phenotype than the newborn mice, it was hypersensitive to
treatment with detergent (SDS) or phorbol ester (PMA). Our
results show that GR is required in keratinocytes for normal
skin development and homeostasis, and that in its absence
mice develop phenotypic and molecular characteristics of
inflammatory skin diseases treated by GCs.
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Figure 1. Mice with keratinocyte-restricted inactivation of glucocorticoid receptor (GR) (GR epidermal knockout (GREKO)) exhibit impaired epidermal barrier
formation. (a) Immunoblotting showing GR loss in epidermis (EPID) of newborn (NB) and adult mice but not in other tissues. (b) Immunofluorescence of tail
epidermal whole mounts showing absence of GR in hair follicles (hf) and sebaceous glands (sg) in addition to interfollicular epidermis (ife). Bar¼ 100 mm. (c)
Impaired epidermal barrier formation of GREKO mice. Epidermal maturation assessed by toluidine blue staining in late (E16.5 to E18.5) GREKO and wild-type
(WT) embryos. GREKO mice showed delayed and altered epidermal barrier formation (red arrows) that did not follow the dorsoventral and anteroposterior pattern
of WT mice (white arrows). Lines indicate the progression of epidermal maturation in WT (white) versus mutant (red) mice.
Figure 2. Abnormal epidermal differentiation and proliferation in glucocorticoid receptor epidermal knockout (GREKO) newborn mice. (a) Hematoxylin and
eosin (H&E)–stained GREKO and wild-type (WT) postnatal (P) skin sections. Dotted line: epidermal (epi)–dermal (der) border. Arrows: hyperkeratosis. Asterisk:
stratum corneum (SC) detachment. Bar¼100 mm. (a0) Epidermal thickness quantitation; Student’s t-test; *Po0.05; **Po0.005. (b–f) P0 skin samples. (b) Electron
microscopy; asterisks: SC detachment. Bar¼20 mm (left), 3 mm (right). (c) Nile red staining; polar (red) and nonpolar (green). Bar¼ 100 mm. (d) Immunostaining.
CDSN, corneodesmosin; FIL, filaggrin; K6, keratin 6; LOR, loricrin. Black thick arrows: specific staining. White arrows: lack of staining. Thin arrows:
parakeratosis. Asterisks: SC detachment. Bar¼ 100 mm (H&E), 50 mm (immunostaining). (e) BrdU-positive keratinocytes (n¼ 12). Mean values±SD are shown.
Student’s t-test; *Po0.05. (f) Immunoblotting.
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RESULTS AND DISCUSSION
Epidermal-specific loss of GR results in impaired barrier
formation
GR was absent in the epidermis of newborn and adult GREKO
mice but not in other tissues, as shown by immunoblotting
(Figure 1a). GR was also absent in hair follicles and sebaceous
glands, as assessed by immunofluorescence in whole mounts
of tail epidermis (Figure 1b). We investigated whether GR
inactivation in keratinocytes affected epidermal barrier
formation by assessing the permeability of toluidine blue
dye in developing embryos. In wild-type (WT) embryos, the
epidermis matured following a dorsoventral and anteroposter-
ior pattern (Figure 1c). Dorsal epidermal barrier initiation
sites were present at embryonic day (E)16.5 (Figure 1c, white
arrows) and by E17.5 the moving front of the epidermal barrier
was evident laterally (Figure 1c, white line). At E18.5, WT
embryos were unstained, consistent with a competent
epidermal barrier. In contrast, GREKO E16.5 and E17.5
embryos showed a delay in barrier formation with initiation
sites scattered throughout the dorsal epidermis, which did not
follow a proper spatiotemporal pattern of development (Figure
1c, GREKO, dorsal view, red arrows). Moreover, the moving
front of the barrier of E17.5 GREKO embryos was irregular
(Figure 1c, lateral view, red line) and at E18.5, colored
remnants were detected on the ventral side of knockout mice,
indicating epidermal immaturity (Figure 1a, GREKO, red
arrows). The epidermis of GREKO E17.5 embryos was much
thinner along the dorsoventral axis compared with WT
(Supplementary Figure S1a–c online), consisting of only a
few cell layers in certain areas (Supplementary Figure S1b
online, arrows). Remarkably, the granular layer and SC were
greatly diminished and SC detachment was frequent (Supple-
mentary Figure S1b online, asterisk). Previous reports on
rodents in which a role for GR in accelerating epidermal
barrier formation was postulated, together with this study
(Figure 1c), strongly suggest that GR has a major role in
regulating the induction of barrier initiation.
Abnormal epidermal differentiation and proliferation in GREKO
newborn mice
After birth, the skin of GREKO mice featured epidermal
hyperplasia (Figure 2a and a0), impaired keratinocyte
differentiation (Figure 2a, arrows) with hyperkeratosis, para-
keratosis (Figure 2d, thin arrows), and extensive areas of SC
detachment (Figure 2a, asterisk). Transmission electron
microscopy further illustrated breakages between the gran-
ular layer and the first corneocyte layer of the SC (Figure 2b,
asterisks). SC lipids are important modulators of barrier
function (Feingold, 2007; Scharschmidt and Segre, 2008; Jin
et al., 2009), therefore, we examined epidermal lipids first by
electron microscopy, and observed no obvious change in
lamellar body extrusion in GREKO mice (data not shown).
However, Nile red staining demonstrated a decreased ratio of
polar (red) to nonpolar (green) lipids in GREKO epidermis
(Figure 2c). Importantly, the observed skin defects improved
by P5, coinciding with anagen (Figure 2a).
We next assessed the expression of epidermal differentia-
tion markers in newborn (P0) GREKO and control mice.
Immunostaining for filaggrin, loricrin, and corneodesmosin
revealed patches of epidermis negative for these epidermal
barrier proteins in GREKO skin (Figure 2d). We also detected
patchy expression of keratin (K)6, a marker of hyperprolifera-
tion commonly seen in skin diseases (Ramot et al., 2009), in
GREKO interfollicular epidermis (Figure 2d). Consistent with the
hyperplasia and K6 staining, we observed a 4-fold increase in
keratinocyte proliferation by in vivo BrdU labeling (Figure 2e).
TUNEL staining revealed a slight, but not statistically
significant, increase in keratinocyte apoptosis in GREKO
epidermis (Supplementary Figure S2 online). Next, we
investigated the processing of pro-filaggrin and observed
decreased levels of both precursor and filaggrin monomer in
GREKO skin (Figure 2f). Furthermore, the activity of the
epidermal-specific non-apoptotic caspase-14, which mediates
pro-filaggrin processing (Presland, 2009), was reduced, as
shown by decreased levels of the active cleaved fragment
(Figure 2f). Decreased filaggrin levels may contribute to
epidermal barrier defects as it is critical for the later stages of
keratinocyte terminal differentiation as well as for the
production of natural moisturizing factor on its degradation
into free amino acids (Hoste et al., 2011). The GREKO skin
phenotype has some similarities to that of GR/ mice in that
both mouse models show defects in epidermal barrier
development, indicating keratinocyte autonomous functions
of GR (Bayo et al., 2008). However, in contrast to GREKO,
GR/ had much more dramatic reductions in both the
expression of differentiation markers and in the layers of the
SC. The different phenotypes may be due to the presence of
dermal GR or to the normal levels of ACTH and corticosterone
in GREKO mice (data not shown). Taken together, our data
suggest that GR is necessary in both the epidermis and the
dermis for proper skin development.
GREKO epidermis shows upregulation of gene markers of
cutaneous inflammatory diseases associated with epidermal
barrier defects
We analyzed the gene expression profile of GREKO versus WT
P0 epidermis by microarrays and identified 293 differentially
expressed genes of which 189 were induced and 104
repressed (Supplementary Table S1 online). A partial gene
list is shown (Figure 3a) along with validation of a gene subset
by real-time reverse-transcription PCR (RT-QPCR) using
independent samples (Figure 3b). GREKO epidermis showed
upregulation of keratins Krt6a, Krt6b, and Krt16, which are
markers of hyperproliferation. Increased Krt6 transcript levels
were consistent with augmented K6 immunostaining in
mutant mice (Figures 2d and 3a). Krt77 and the epithelial-
specific transcription factor Elf5, two genes whose expression
normally peaks during embryogenesis in early stages of
epidermal maturation, were also induced in GREKO epider-
mis. We found induction of numerous genes mapping to the
epidermal differentiation complex (EDC), a cluster of related
genes involved in epidermal differentiation as well as host
defense responses (Sugiura et al., 2005; Segre, 2006; Hoffjan
and Stemmler, 2007; de Koning et al., 2011). Among the 75
most upregulated genes were EDC members including
multiple small proline-rich proteins (Sprrs), late cornified
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envelope proteins (Lces), repetin (Rptn), peptidoglycan
recognition protein 3 (Pglyrp3), and S100 calcium-binding
proteins S100a8 and S100a9 (Figure 3a and b). The
upregulation in group 3 Lce genes is noteworthy, as their
expression is normally restricted to internal epithelia and is
only induced in the epidermis under conditions of stress
(Jackson et al., 2005; De Cid et al., 2009). We also found
strong induction of proteases and protease inhibitors that
participate in the normal maintenance of the SC, such as
matrix metallopeptidase Mmp3, kallikrein (Klk)-related pep-
tidases, and secretory leukocyte peptidase inhibitor (Slpi).
Many genes involved in lipid metabolism and transport had
altered expression in GREKO epidermis, including lipase
endothelial (Lipg), ATP-binding cassette, sub-family G,
member 1 (Abcg1) and sub-family A (ABC1), member 12
(Abca12), arachidonate 12-lipoxygenase (Alox12), and phos-
pholipase A2, group IVE (Pla2g4e) (Supplementary Table S1
online). GR is a known modulator of lipid metabolism
(Revollo and Cidlowski, 2009; Elias, 2010; Nicolaides et al.,
2010), and the alterations in epidermal lipids in its absence
could contribute to the changes in Nile red staining and the
observed fragility of the SC.
Importantly, we found upregulation of genes involved in
cutaneous innate immune responses, such as thymic stromal
lymphopoietin (Tslp), IL 33 (Il33), epiregulin (Ereg), and B-
cell leukemia 3 (Bcl3) (Figure 3a and b). Almost 50% of the
genes upregulated greater than 2-fold in GREKO mice were
reported markers of inflammatory skin disorders (Sugiura
et al., 2005; Roberson and Bowcock, 2010). In fact, a high
percentage of the genes induced in GREKO epidermis have
been reported as overexpressed in the skin of AD patients
(Sugiura et al., 2005; Cork et al., 2009; Elias, 2010). Tslp has
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Figure 3. Gene expression changes and skin phenotype indicate an intrinsic epidermal stress response of glucocorticoid receptor epidermal knockout (GREKO)
mice to barrier disruption. (a) Selected list of differentially expressed genes in GREKO relative to wild-type (WT) newborn epidermis grouped by gene ontology.
(b) RT-QPCR validation of selected genes was performed in an independent experiment with at least three individuals of each genotype. (c) Increased
degranulation of mast cells and elevated numbers of macrophages indicate an abnormal immune response in GREKO mice. Normal mast cells in WT dermis
(black arrows) and degranulated mast cells in the upper dermis of GREKO mice (red arrows) are indicated. F480 antibody–stained macrophages. Bars¼100 mm
(outer panels), 50 mm (middle panels).
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a major role in AD, indeed its overexpression in keratinocytes
is sufficient to trigger an AD-like disease in mice (Li et al.,
2005, 2006; Zhang et al., 2009); importantly, Tslp
levels in keratinocytes are transcriptionally repressed by
ligand-activated GR (Li et al., 2006; Surjit et al., 2011).
Together with Tslp, the induction of Bcl3 in GREKO epidermis
suggests alterations in the innate immune response of these
animals as it is inducible by Th2 cytokines and is over-
expressed in lesional skin of AD patients (Bu¨chau et al.,
2009). Although the immune response may contribute to
changes in Bcl3 expression, we found that it was
also upregulated in cultured GREKO keratinocytes, indicating
cell autonomous effects of GR (Supplementary Figure S3a
online). Moreover, treatment with dexamethasone, but not
the GR antagonist RU486, inhibited Bcl3 expression in WT
keratinocytes, both in the absence and presence of IL6, a
known inducer of Bcl3 (Supplementary Figure S3b online).
The list of differentially expressed genes in Supplementary
Table S1 online was configured using a cutoff of 1.5-fold
change relative to WT, however, we also detected and
confirmed by RT-QPCR the induction of the STAT3 (Stat3)
gene (1.3-fold by microarray; 3-fold by RT-QPCR) in mutant
epidermis (Figure 3a and b). Remarkably, we detected both
overlapping and distinct set of genes in gene expression
profiling for GREKO versus GR/ mice (Figure 3, Table 1;
Sevilla et al., 2010). There was strong upregulation of Krt77
and Elf5, as well as downregulation of known GR target genes
such as alcohol dehydrogenase 1 (Adh1) and Fkbp51 (Sevilla
et al., 2010); conversely, some EDC genes such as Sprr2d and
Rptn, were oppositely regulated in the GR/ and GREKO.
Importantly, changes in the expression of genes associated
with skin immunity such as Tslp and Bcl3 were detected
in GREKO but not in GR/ mice. The lack of changes in
expression of these genes in GR/ mice is consistent with
the fact that we have not detected immune infiltrates in
GR/ skin (Bayo et al., 2008; Sevilla et al., 2010). However,
we cannot establish a direct comparison between the gene
expression profiles of GREKO and GR/ mice as the analyses
were performed in newborn mouse epidermis and E18.5 total
skin, respectively.
We evaluated macrophages and mast cells, which are
increased in AD skin. GREKO skin had infiltration of
macrophages (Figure 3c) and extensive areas with degranu-
lated mast cells in the upper dermis (Figure 3c, red arrows).
Moreover, there is increased degranulation of mast cells
in GREKO embryonic skin indicating that the observed
immune response occurs independently of exposure to the
external environment and is driven by changes in commu-
nication between immune cells and keratinocytes lacking
GR (Supplementary Figure S4 online). The IL-1 family
member Il33, upregulated 2.6-fold in GREKO epidermis,
activates mast cell degranulation in the presence of IgE,
and has increased levels in lesions and blood of AD patients
(Liew et al., 2010).
Altogether, the histological characterization of GREKO
mice along with the observed transcriptomic changes
suggests that the epidermal-specific loss of GR triggers a skin
phenotype resembling key features of AD.
Increased ERK/AKT and STAT3 signaling in GREKO epidermis
Total GR inactivation results in increased activity of the
mitogen-activated protein kinase ERK in keratinocytes (Bayo
et al., 2008). We detected phosphorylated ERK (p-ERK) in the
epidermal basal layer of GREKO late embryos and newborn
mice in addition to its normal localization in the upper layers
(Figure 4a). Mitogen-activated protein kinases propagate
inflammatory signaling and ligand-bound GR is known to
interfere with the activating phosphorylation of members of
this kinase family, including ERK (De Bosscher and Haege-
man, 2009). The increase in ERK phosphorylation in GREKO
epidermis likely contributes to the observed inflammation
and hyperproliferation and may contribute to the elevated
levels of EDC genes and Krt6/Krt16, among others, as they are
AP-1 targets (Ramot et al., 2009). Acutely transforming
retrovirus AKT8 in rodent T cell lymphoma (AKT) activity
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Figure 4. Altered signaling in glucocorticoid receptor epidermal knockout
(GREKO) epidermal keratinocytes. (a) Increased extracellular signal–regulated
kinase (ERK) activity in GREKO epidermis. Immunostaining shows
phosphorylated ERK in wild-type (WT) and GREKO suprabasal keratinocytes
(arrowheads) and in basal keratinocytes (arrows) of GREKO epidermis (n¼ 8).
Bar¼100 mm (large panels), 65 mm (insets). (b) Immunoblotting (left) and
quantitation (right) demonstrates increased phosphorylated signal transducer
and activator of transcription (p-STAT3)/STAT-3 and p-AKT/AKT ratios as well
as elevated S100A9 levels in GREKO newborn epidermis (n¼12). Actin was
used as a loading control. Mean values±SD are shown. Asterisks denote
statistically significant differences among genotypes, as determined by
Student’s t-test (*Po0.05).
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was also elevated in the GREKO epidermis by approximately
2-fold (Figure 4b). AKT is critical for proper epidermal
development (Peng et al., 2003), and is involved in the
initiation of keratinocyte terminal differentiation as well as in
the regulation of filaggrin processing and cornified envelope
formation (Calautti et al., 2005; O’Shaughnessy et al., 2005).
AKT activity has been shown to transiently increase during
barrier acquisition and its inhibition impairs barrier formation
(O’Shaughnessy et al., 2009). Given that ligand-bound GR
interferes with the phosphatidylinositol-3-kinase signaling
pathway and its effector kinase AKT in skin (Leis et al., 2004),
the observed defects in epidermal barrier acquisition in
GREKO mice may be at least partially due to misregulation of
this pathway.
Cross-talk between GR and STATs has a role in the
regulation of cell proliferation, differentiation, and survival,
by modulating gene transcription in a cell-type–specific
manner (Liberman et al., 2007). Importantly, STAT3 is
activated in epidermal keratinocytes of psoriatic patients
(Sano et al., 2008). Given the increased Stat3 transcript levels
in GREKO epidermis, we analyzed STAT3 protein expression
and activity (Figure 4b). STAT3 protein levels were only
slightly increased in mutant P0 epidermis; however, we
detected a 2.5-fold increase of the phosphorylated (p)-STAT3/
STAT3 ratio (Figure 4b). Depending on cellular context, GCs
have been shown to inhibit or synergize with the STAT3
transcription factor in terms of its phosphorylation and
binding to chromatin (Langlais et al., 2008; De Bosscher
and Haegeman, 2009; Bertucci et al., 2010). Our results
suggest that in the developing epidermis, STAT3 phosphor-
ylation is negatively regulated by GR, which is particularly
relevant as GCs are frequently used to treat psoriatic lesions
(Sano et al., 2008). The expression of S100A9, a marker of
AD and psoriasis, was also increased in GREKO relative to WT
epidermis (Figure 4b). Consistent with the in vivo data,
cultured GREKO keratinocytes showed relative increases in
STAT3 and ERK phosphorylation as compared with WT
(Supplementary Figure S5 online).
Adult GREKO mice show an exacerbated inflammatory response
to epidermal challenge
Adult GREKO skin had a mild phenotype with slightly
increased proliferation and patches of epidermis negative
for filaggrin and loricrin (Figure 5a, left panels; Figure 5b;
Supplementary Figure S6a online). Similar yields of cornified
envelopes were obtained from GREKO and WT (data not
shown), which were morphologically similar with no
changes in fragile/rigid ratios (Supplementary Figure S6b
and c online). These data together with the normal
histological appearance suggest that barrier function is intact
in adult GREKO mice. Altogether, these data suggest that GR
has distinct roles in the epidermis during development and in
adulthood. Contrary to WT, topical treatment with the GC
synthetic analog dexamethasone did not cause epidermal
atrophy or keratinocyte growth inhibition in GREKO mice,
demonstrating that the anti-proliferative effects of GCs
require functional GR in keratinocytes (Figure 5a and b). As
epidermal defects during development may cause impaired
responses in adulthood, we examined the consequences of
GR loss-of-function in epidermal barrier repair after injury.
Topical treatment of adult WT mice with the detergent SDS,
an irritant that mimicks contact dermatitis by disrupting the
epidermal barrier, elicited epidermal hyperplasia and hyper-
keratosis (Figure 5c). In GREKO mice, this response was
exaggerated with more pronounced hyperplasia and hyper-
keratosis as well as parakeratosis (Figure 5c). A similar
exacerbated response was found in GREKO mice treated with
the tumor promoter PMA (Figure 5c). In some cases, both SDS
and PMA elicited even more severe phenotypes in GREKO
mice, with intraepithelial infiltrates and epidermal destruc-
tion (Figure 5c, lower panels, asterisks). Both SDS and PMA
treatments induced elevated levels of K6 (Figure 5d, upper
panels) consistent with its upregulation in GREKO-developing
skin (Figures 2 and 3). ERK activity was higher in adult GREKO
relative to WT mice either in the absence or presence of
topical treatments (Figure 5d, lower panels). We observed
increased SDS-induced nuclear translocation of STAT3 by
immunohistochemistry in GREKO epidermis, especially in the
basal layer, compared with WT (Figure 5e). The levels of p-
STAT3 were clearly increased in control and mutant mice
after SDS treatment (Figure 5e0). Collectively, our data
reinforce the importance of GR in skin physiology as well
as in the pathogenesis of skin diseases and indicate that
understanding the transcriptional program by which GR
modulates keratinocyte differentiation could contribute to
rationale design of therapies for treating cutaneous inflam-
matory diseases.
MATERIALS AND METHODS
Animal experimentation and treatments
GRloxP/loxP and K5-Cre mice have been reported (Tronche et al.,
1999; Ramirez et al., 2004); see Supplementary Figure S7 online for
a diagram of gene-targeting strategy. Animal experimentation was
conducted according to the current Spanish and European regula-
tions and approved by our institution’s ethics committee. When
indicated, GREKO (K5-cre//GRloxP/loxP) and their control littermates
(0cre//GRloxP/loxP) were obtained by cesarean derivation. Topical
treatments included dexamethasone (8mg per mouse; daily for
72 hours), PMA (8mg per mouse for 48 hours; both from Sigma,
St Louis, MO), and SDS (10%, daily for 5 days; Merck, Darmstadt,
Germany).
Epidermal dye permeability assay was performed with 1%
toluidine blue dye (Sigma) as described (Byrne et al., 2010).
Histological and immunohistochemical analysis
Tail epidermal whole mounts from 8-week-old GREKO and control
littermates were prepared and stained as described (Braun et al.,
2003), and images collected with a Leica TCS SL confocal
microscope (Wetzlar, Germany). Total embryos (E16.5, E17.5, or
E18.5) or dorsal skin samples were collected at postnatal days P0,
P1, P2, P5 (n¼ 62), and P56 (n¼ 87), fixed in 4% paraformaldehyde
or 70% ethanol and embedded in paraffin. Histopathological
analysis was performed as described (Bayo et al., 2008). For lipid
staining, sections were incubated with 1mgml1 Nile Red (Sigma) in
phosphate-buffered saline along with 40-6-diamidino-2-phenylindole
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for 5minutes at room temperature. Mast cells were detected using
0.1% toluidine blue for 3minutes.
Epidermal thickness was assessed using images of hematoxylin
and eosin–stained paraffin skin sections from E16.5, E18.5, P0, and
P2 mice, counting at least 10 1-mm fields per slide using MetaMorph
software (Premier Offline 7.0; Molecular Devices, Downingtown,
PA). Experiments were performed in at least five individuals of each
genotype, and statistical significance was assessed using the
Student’s t-test, (Po0.05).
Analysis of proliferation and apoptosis
BrdU incorporation was assessed by immunohistochemistry (anti-BrdU,
biotest, Roche, Indianapolis, IN) in paraffin-embedded sections from
mice injected with BrdU 1hour before killing (130 mg g1 of body
weight, Roche). Apoptotic cells were labeled in paraffin sections
with the In Situ Cell Death Detection kit (Roche), before mounting
with 40-6-diamidino-2-phenylindole and analysis under a fluores-
cence microscope (Leica DM 1000). Experiments were performed at
least in five individuals of each genotype and age, and statistical
significance was assessed using the Student’s t-test (Po0.05).
Transmission electron microscopy
Skin samples were fixed in 2.5% glutaraldehyde/2.5% paraformal-
dehyde/phosphate-buffered saline (pH 7.2) for 15 hours at 20 1C,
postfixed with 1% OsO4/phosphate-buffered saline in the dark at
4 1C followed by dehydration in an ascending water/acetone series,
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Figure 5. Exacerbated inflammatory responses to epidermal challenge of glucocorticoid receptor epidermal knockout (GREKO) adult mice. (a) Hematoxylin
and eosin (H&E)–stained skin sections of control (vehicle, V) and dexamethasone (Dex)-treated GREKO and wild-type (WT) adult mice (n¼ 8). Bar¼50 mm. (b)
Quantitation of BrdU-positive keratinocytes in a (n¼8). Mean values±SD; Student’s t-test; *Po0.05. (c) H&E-stained skin sections showing exaggerated stress
response in GREKO adult mice on topical SDS and acute phorbol ester (PMA) treatment (n¼ 18). Asterisks: intraepithelial inflammatory infiltrates. Bar¼100 mm
(upper); 60 mm (lower). (d) Immunostaining of skin sections in c using K6 and phosphorylated extracellular signal–regulated kinase (p-ERK) antibodies.
Bars¼ 100 mm. (e) Immunostaining of skin sections (untreated and SDS-treated) using STAT3. Bar¼ 100 mm. (e0) Immunoblotting of skin sections in e using signal
transducer and activator of transcription 3 (STAT3) and phosphorylated (p)-STAT3 antibodies. Actin, loading control.
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and embedded in AGAR 100 epoxy resin (Agar Scientific, Stansted,
UK). Sections obtained by an ultramicrotome (Reichert Ultracut S;
Leica) were stained with 2% uranyl acetate and lead citrate at
various concentrations, and examined with a transmission electron
microscope (CEM 902A; Zeiss, Oberkochen, Germany) at an
acceleration voltage amounting to 80 kV.
Epidermal preparation, RNA isolation, microarray analysis, and
quantitative reverse transcriptase–PCR
Mouse dorsal epidermis was separated from the dermis following
incubation with 1mgml1 dispase II (Roche) for 2 hours at room
temperature and total RNA isolated using Trizol (Invitrogen,
Molecular Probes, Eugene, OR). RNA was purified by standard
procedures (Qiagen, Valencia, CA) and its integrity tested by the
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Four
microarrays (Affymetrix GeneChip Mouse Gene 1.0 ST, Santa Clara, CA)
of GREKO and WT P0 epidermis were analyzed. Microarray hybridi-
zation, data normalization, and analysis were carried on the genomic
platform at the Centro de Investigacio´n del Ca´ncer de Salamanca, as
described on their webpage (http://ubioinfo.cicancer.org). The gene
list with the 293 differentially expressed genes with statistical
significance (FDRo0.06) in GREKO versus WT (considering fold-
changes of at least 1.5-fold) is in Supplementary Table S1 online.
A measure of 1mg of total RNA was reverse transcribed by using
oligo-dT (Fermentas, Burlington, Ontario, Canada) followed by
quantitative PCR using specific oligonucleotides (Supplementary
Table S2 online) for each of the genes tested and FastStart Universal
SYBR Green Master ROX (Roche) in an Applied Biosystems 7500
Fast real-time PCR system (Applied Biosystems, Carlsbad, CA). At
least three biological replicates were used for each experimental
group and technical triplicates were assessed to calculate the mean
value±SD. Statistical significance was calculated using the Stu-
dent’s t-test, Po0.05.
Immunoblotting and antibodies
Whole-cell extracts and immunoblotting were performed as
described (Bayo et al., 2008). Experiments were performed in at
least three individuals of each genotype.
Polyclonal antibodies to GR (sc-1004), casp-14 (sc-5628), ERK
(sc-154), and AKT (sc-1619) and mAb for K14 (LL009) were from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against
phosphorylated ERK (Thr202/Tyr204; #4376), p-AKT (ser-473;
#9271), STAT3 (#9132), and p-STAT3 (Tyr705 D3A7; #9145) were
from Cell Signaling Technology (Beverley, MA). The anti-keratin K5
(PRB-160P), K6 (PRB-169P), K10 (PRB-159P), loricrin (PRB-145P),
and filaggrin (PRB-417P) antibodies were from Covance (Babco,
Berkeley, CA). F4/80 antibody (AbD serotec, MorphoSys, Oxford,
UK), actin antibody (A-2066, Sigma), and anti-S100A9 (R&D
Systems, Minneapolis, MN) were used. The mAb F28-27 specific
for corneodesmosin was a gift from the Serre lab (Centre National de
la Recherche Scientifique, Toulouse, France; Serre et al., 1991).
Secondary peroxidase-conjugated anti-rabbit (GE Healthcare,
Waukesha, WI) and anti-goat antibodies (Jackson ImmunoResearch,
West Grove, PA) and secondary biotin-conjugated anti-rabbit or
anti-mouse antibodies (Jackson ImmunoResearch) were used.
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